Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Annals of Hematology|June 13, 2025
Efficacy and safety of Glofitamab in patients with R/R DLBCL in real life setting- a retrospective studyRonit Gurion, Dmitri Guz, Meirav Kedmi, et al.
Haematologica|February 10, 2015
Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experienceYair Herishanu, Neta Goldschmidt, Osnat Bairey, et al.
American Journal of Hematology|June 19, 2019
Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter studyChava Perry, Sharon Ben Barouch, Neta Goldschmidt, et al.
Annals of Hematology|June 19, 2023
Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma-a real-world multicenter retrospective cohort studyTamar Berger, Tzippy Shochat, Shlomzion Aumann, et al.
European Journal of Haematology|June 28, 2018
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trialsErel Joffe, Neta Goldschmidt, Osnat Bairey, et al.
Hematological Oncology|June 23, 2017
Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survivalErel Joffe, N Ariela Arad, Osnat Bairey, et al.
Anticancer Research|November 7, 2018
Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in IsraelMichal Inbar, Yair Herishanu, Neta Goldschmidt, et al.
European Journal of Haematology|February 9, 2026
Obinutuzumab Maintenance in Follicular Lymphoma Is Associated With Better Progression Free Survival and Comparable ToxicityRenana Robinson, Tamar Berger, Tzippy Shochat, et al.
European Journal of Haematology|April 25, 2023
Risk factors and outcomes of COVID-19 in adult patients with hematological malignancies: A single-center study showing lower than expected rates of hospitalization and mortalityShlomzion Aumann, Uria Tsubary, Boaz Nachmias, et al.
Leukemia Research|June 2, 2019
Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemiaTamar Tadmor, Ilana Levy, Yair Herishanu, et al.
Pageof 8